ProKidney Corp.
PROKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ProKidney Corp. focuses on Biotechnology services and products. ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company carries a $573.9M market cap, placing it firmly in the small-cap category. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Market Cap
$573.9M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-3.30
EPS (TTM)
$-0.53
EPS (Fwd)
$-0.58
ROE
-49.4%
ROA
-30.1%
Cash
$224.9M
Total Debt
$3.8M
Free CF
-$78.6M
52W Change
140.8%
Annual Financials
Cash vs Debt
ProKidney Corp. holds $224.9M in cash against $3.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$78.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -49.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.75 means PROK is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, PROK has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ProKidney Corp.'s trajectory.